{"id":"https://openalex.org/W4393096201","doi":"https://doi.org/10.1158/1538-7445.am2024-4081","title":"Abstract 4081: rhIL-7-hyFc (efineptakin-alfa, NT-I7) increases tumor-specific CD8+ T cells despite FOLFOX cytotoxicity effect","display_name":"Abstract 4081: rhIL-7-hyFc (efineptakin-alfa, NT-I7) increases tumor-specific CD8+ T cells despite FOLFOX cytotoxicity effect","publication_year":2024,"publication_date":"2024-03-22","ids":{"openalex":"https://openalex.org/W4393096201","doi":"https://doi.org/10.1158/1538-7445.am2024-4081"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2024-4081","doi":"https://doi.org/10.1158/1538-7445.am2024-4081","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2024-4081","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067777948","display_name":"Soung-Min Lee","orcid":"https://orcid.org/0000-0003-0653-9739","observed_orcids":["https://orcid.org/0000-0003-0653-9739"]},"institutions":[{"id":"https://openalex.org/I4405267539","display_name":"NeoImmuneTech, Inc. (United States)","ror":"https://ror.org/035t43f61","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267539"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Soung-Min Lee","raw_affiliation_strings":["1NeoImmuneTech, Inc., Gyeongsangbuk-do, Republic of Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1NeoImmuneTech, Inc., Gyeongsangbuk-do, Republic of Korea;","institution_ids":["https://openalex.org/I4405267539"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100743283","display_name":"Mi-Young Kim","orcid":"https://orcid.org/0000-0003-2395-5822","observed_orcids":["https://orcid.org/0000-0003-2395-5822"]},"institutions":[{"id":"https://openalex.org/I4405267539","display_name":"NeoImmuneTech, Inc. (United States)","ror":"https://ror.org/035t43f61","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267539"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Miyoung Kim","raw_affiliation_strings":["1NeoImmuneTech, Inc., Gyeongsangbuk-do, Republic of Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1NeoImmuneTech, Inc., Gyeongsangbuk-do, Republic of Korea;","institution_ids":["https://openalex.org/I4405267539"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016887010","display_name":"Sara Ferrando\u2010Mart\u00ednez","orcid":"https://orcid.org/0000-0003-0721-555X","observed_orcids":["https://orcid.org/0000-0003-0721-555X"]},"institutions":[{"id":"https://openalex.org/I4405267539","display_name":"NeoImmuneTech, Inc. (United States)","ror":"https://ror.org/035t43f61","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267539"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara Ferrando-Mart\u00ednez","raw_affiliation_strings":["2NeoImmuneTech, Inc., Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2NeoImmuneTech, Inc., Rockville, MD","institution_ids":["https://openalex.org/I4405267539"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061987388","display_name":"Sun\u2010Kyoung Im","orcid":"https://orcid.org/0000-0002-5513-2559","observed_orcids":["https://orcid.org/0000-0002-5513-2559"]},"institutions":[{"id":"https://openalex.org/I4405267539","display_name":"NeoImmuneTech, Inc. (United States)","ror":"https://ror.org/035t43f61","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267539"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sun-Kyoung Im","raw_affiliation_strings":["1NeoImmuneTech, Inc., Gyeongsangbuk-do, Republic of Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1NeoImmuneTech, Inc., Gyeongsangbuk-do, Republic of Korea;","institution_ids":["https://openalex.org/I4405267539"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053465855","display_name":"Mankyu Ji","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267539","display_name":"NeoImmuneTech, Inc. (United States)","ror":"https://ror.org/035t43f61","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267539"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mankyu Ji","raw_affiliation_strings":["1NeoImmuneTech, Inc., Gyeongsangbuk-do, Republic of Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1NeoImmuneTech, Inc., Gyeongsangbuk-do, Republic of Korea;","institution_ids":["https://openalex.org/I4405267539"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022383639","display_name":"Donghoon Choi","orcid":"https://orcid.org/0000-0002-2009-9760","observed_orcids":["https://orcid.org/0000-0002-2009-9760"]},"institutions":[{"id":"https://openalex.org/I4405267539","display_name":"NeoImmuneTech, Inc. (United States)","ror":"https://ror.org/035t43f61","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267539"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Donghoon Choi","raw_affiliation_strings":["1NeoImmuneTech, Inc., Gyeongsangbuk-do, Republic of Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1NeoImmuneTech, Inc., Gyeongsangbuk-do, Republic of Korea;","institution_ids":["https://openalex.org/I4405267539"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405267539"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"6_Supplement","first_page":"4081","last_page":"4081"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.5634999871253967,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.5634999871253967,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.20250000059604645,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.19580000638961792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/interleukin-7","display_name":"IL-7","score":0.8450000286102295},{"id":"https://openalex.org/keywords/folfox","display_name":"FOLFOX","score":0.8009999990463257},{"id":"https://openalex.org/keywords/oxaliplatin","display_name":"oxaliplatin","score":0.828000009059906},{"id":"https://openalex.org/keywords/5-fluorouracil","display_name":"5-fluorouracil","score":0.9399999976158142},{"id":"https://openalex.org/keywords/leucovorin","display_name":"leucovorin","score":0.9639999866485596},{"id":"https://openalex.org/keywords/tumor-specific-cd8-t-cells","display_name":"tumor-specific CD8+ T cells","score":0.7979999780654907},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.8600000143051147},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.5139999985694885},{"id":"https://openalex.org/keywords/chemotherapy-toxicity","display_name":"chemotherapy toxicity","score":0.4959999918937683},{"id":"https://openalex.org/keywords/lymphodepletion","display_name":"lymphocyte depletion","score":0.5669999718666077},{"id":"https://openalex.org/keywords/mc38-colon-carcinoma","display_name":"MC38 colon carcinoma","score":0.5799999833106995},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.5870000123977661}],"concepts":[{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.7457102537155151},{"id":"https://openalex.org/C2778260052","wikidata":"https://www.wikidata.org/wiki/Q117636","display_name":"FOLFOX","level":5,"score":0.7409146428108215},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.5455590486526489},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4696449637413025},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.38577523827552795},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33944475650787354},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.2901673913002014},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.2067834436893463},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.19487157464027405},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1680971384048462},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.07189878821372986},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.06459978222846985}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2024-4081","doi":"https://doi.org/10.1158/1538-7445.am2024-4081","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2024-4081","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9922999739646912,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4282929562","https://openalex.org/W4282967910","https://openalex.org/W4391808760","https://openalex.org/W4392709632","https://openalex.org/W2885502149","https://openalex.org/W4313368440","https://openalex.org/W2954676610","https://openalex.org/W4411151975","https://openalex.org/W3083542804","https://openalex.org/W2127563925"],"abstract_inverted_index":{"Abstract":[0],"rhIL-7-hyFc":[1,297],"(efineptakin-alfa;":[2],"NT-I7)":[3,299],"is":[4,46,101],"a":[5,40,102,161,200],"potent":[6],"T":[7,53,70,84,95,230,244,264,303],"cell":[8],"amplifier,":[9],"comprised":[10],"of":[11,14,23,68,81,106,124,155,175,178,181,226,241,277,280,312],"two":[12],"molecules":[13],"interleukin-7":[15],"(IL-7)":[16],"fused":[17],"to":[18,49,136,151,261],"the":[19,32,66,79,122,134,153,173,179,206,215,223,238,247,267,270,273,278,313],"hybrid":[20],"Fc":[21],"domain":[22],"IgD/IgG4":[24],"immunoglobulin.":[25],"NT-I7":[26,61,142,159,171,182,281],"safely,":[27],"significantly,":[28],"and":[29,90,109,115,269],"persistently":[30],"increases":[31,65,300],"absolute":[33,224],"lymphocyte":[34],"counts":[35],"(ALC)":[36],"in":[37,39,52,72,97,127,146,160,203],"humans":[38],"dose-proportional":[41],"manner.":[42],"Importantly,":[43],"this":[44,147],"increase":[45,51,240,262],"primarily":[47],"due":[48],"an":[50],"cells":[54,71,96,119,245,265,304],"(1).":[55],"Previous":[56],"studies":[57],"have":[58],"shown":[59],"that":[60,111,170,254],"not":[62,236,257],"only":[63],"significantly":[64,212],"number":[67],"CD8+":[69,83,94,229,243,302],"peripheral":[73],"blood":[74],"but":[75],"also":[76,132],"dramatically":[77],"boosts":[78],"presence":[80],"tumor-infiltrating":[82],"cells,":[85],"including":[86],"both":[87],"tumor-specific":[88,242,263,301],"(p15E+PD-1+)":[89],"tumor":[91,129,165,227,268],"non-specific":[92,228],"(PD-1-)":[93],"mice":[98],"(2).":[99],"FOLFOX":[100,125,157,194,219,221,234,255,306],"chemotherapy":[103],"regimen":[104],"composed":[105],"5-fluorouracil,":[107],"leucovorin,":[108],"oxaliplatin":[110],"inhibits":[112],"DNA":[113],"duplication":[114],"eradicates":[116],"rapidly":[117],"dividing":[118,139],"(3).":[120],"Although":[121],"mechanism":[123],"results":[126,168],"direct":[128],"killing,":[130],"it":[131],"has":[133],"potential":[135],"kill":[137],"newly":[138],"lymphocytes":[140],"during":[141],"treatment":[143],"(4-6).":[144],"Therefore,":[145],"study,":[148],"we":[149],"aimed":[150],"evaluate":[152],"feasibility":[154],"combining":[156],"with":[158,218],"syngeneic":[162],"MC38":[163],"mouse":[164],"model.":[166],"Our":[167],"show":[169],"improves":[172],"efficacy":[174],"FOLFOX,":[176],"irrespective":[177,276],"timing":[180,279],"administration:":[183],"simultaneous":[184],"administration":[185],"or":[186,190],"delayed":[187],"3":[188],"hours,":[189],"2":[191],"days":[192],"after":[193],"administration.":[195,282],"This":[196],"improvement":[197],"persists":[198],"despite":[199,305],"significant":[201],"decrease":[202],"ALC":[204,216],"for":[205,316],"first":[207],"6":[208],"days,":[209],"which":[210],"was":[211],"lower":[213],"than":[214],"observed":[217],"alone.":[220],"decreases":[222],"numbers":[225],"cells.":[231],"However,":[232],"adding":[233],"does":[235,256],"affect":[237],"NT-I7-driven":[239],"within":[246,266],"tumor.":[248],"Taken":[249],"together,":[250],"our":[251],"data":[252],"demonstrate":[253],"compromise":[258],"NT-I7\u2019s":[259],"ability":[260],"combination":[271],"enhances":[272],"anti-tumor":[274],"response":[275],"Citation":[283],"Format:":[284],"Soung-Min":[285],"Lee,":[286],"Miyoung":[287],"Kim,":[288],"Sara":[289],"Ferrando-Mart\u00ednez,":[290],"Sun-Kyoung":[291],"Im,":[292],"Mankyu":[293],"Ji,":[294],"Donghoon":[295],"Choi.":[296],"(efineptakin-alfa,":[298],"cytotoxicity":[307],"effect":[308],"[abstract].":[309],"In:":[310],"Proceedings":[311],"American":[314],"Association":[315],"Cancer":[317,335],"Research":[318],"Annual":[319],"Meeting":[320],"2024;":[321],"Part":[322],"1":[323],"(Regular":[324],"Abstracts);":[325],"2024":[326],"Apr":[327],"5-10;":[328],"San":[329],"Diego,":[330],"CA.":[331],"Philadelphia":[332],"(PA):":[333],"AACR;":[334],"Res":[336],"2024;84(6_Suppl):Abstract":[337],"nr":[338],"4081.":[339]},"counts_by_year":[],"updated_date":"2026-09-23T05:00:35.095934","created_date":"2024-03-23T00:00:00"}